Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis.
OBJECTIVE
To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis.


METHODS
Outpatient hemodialysis center.


METHODS
Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer.


METHODS
Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks.


RESULTS
Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean +/- SD difference (estimate of bias) between assays was -1.10 +/- 1.35 mg/L. The limits of agreement (mean difference +/- 1.96 x SD) between them were -3.80-1.60 mg/L.


CONCLUSIONS
Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.
Kingery
J R
JR
Department of Pharmacy, Clarian Health Partners, Inc., Indiana University Hospital, Indianapolis, USA.
Sowinski
K M
KM
Kraus
M A
MA
Klaunig
J E
JE
Mueller
B A
BA
D000900:Anti-Bacterial Agents / Q000097:blood*; D017248:Enzyme Multiplied Immunoassay Technique; D005454:Fluorescence Polarization; D006801:Humans; D007118:Immunoassay; D014640:Vancomycin / Q000097:blood*
D000900:Anti-Bacterial Agents; D014640:Vancomycin